Back to test list

KRAS and NRAS screen

Also known as: RAS panel, KRAS and NRAS gene test

Test category:

Oncology - Colorectal cancer

Use of test

Purpose:

The presence of specific activating mutations in the KRAS and NRAS genes in certain malignancies (for example, metastatic colorectal cancer) indicates a reduced likelihood of treatment response to anti-EGFR therapy.
This is a test for mutations in the KRAS and NRAS genes only. Combinations of KRAS, NRAS and other genes are included in our full FIND-IT panel and focussed panels for colorectal cancer, lung cancer and melanoma.

Utility:

A normal test result (no mutations) indicates that the patient's tumour is likely to respond to anti-EGFR therapies. An abnormal test result (specific mutations identified) indicates that the tumour is likely to be resistant to anti-EGFR therapies.

Ethical considerations:

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

Methodology:

Testing of targeted mutations in the KRAS and NRAS genes (at codons 12, 13, 59, 61, 117 and 146 in both genes).

Requesting the test

Ordering:

This test is usually requested by an oncologist. Please use the specific request form (see link below).

Request Form:

Link to somatic mutation request form.

Sample required:

Formalin-fixed, paraffin embedded tissue (FFPE) - 15 sections of 4 uM thickness, dried overnight at 37°C onto charged/coated slides.

Special instructions:

Please stain the first section with H&E, and label each slide with patient and block identifiers. Label the unstained sections sequentially (slides 2-15). The request should be accompanied by the somatic mutation request form (above) and a copy of the original histopathology report.

Turnaround time:

5-10 business days.

Price:

This test has a Medicare rebate which, subject to the requirements of the Medicare descriptor being met, may cover all or part of the cost.

Rebate:

The Medicare details, including descriptor and schedule fee, are listed under MBS item 73338.